The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | The EMN22 trial: daratumumab monotherapy in newly diagnosed stage 3B AL amyloidosis
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses EMN22 (NCT04131309), a prospective Phase II study that investigated daratumumab monotherapy in newly diagnosed patients with stage 3B light chain (AL) amyloidosis. The study’s primary endpoint was met, with a 65% overall survival (OS) rate at six months. Prof. Kastritis highlights that the median OS of 11 months was significantly greater than in historical controls. The monotherapy also resulted in encouraging rates of hematological and cardiac response, and no unexpected toxicities were reported. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
